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ABSTRACT
Introduction: Pain is the commonest reason that
patients present to an emergency department (ED), but
it is often not treated effectively. Patient controlled
analgesia (PCA) is used in other hospital settings but
there is little evidence to support its use in emergency
patients. We describe two randomised trials aiming to
compare PCA to nurse titrated analgesia (routine care)
in adult patients who present to the ED requiring
intravenous opioid analgesia for the treatment of
moderate to severe pain and are subsequently admitted
to hospital.
Methods and analysis: Two prospective multi-
centre open-label randomised trials of PCA versus
routine care in emergency department patients who
require intravenous opioid analgesia followed by
admission to hospital; one trial involving patients with
traumatic musculoskeletal injuries and the second
involving patients with non-traumatic abdominal pain.
In each trial, 200 participants will be randomised to
receive either routine care or PCA, and followed for the
first 12 h of their hospital stay. The primary outcome
measure is hourly pain score recorded by the
participant using a visual analogue scale (VAS) over
the 12 h study period, with the primary statistical
analyses based on the area under the curve of these
pain scores. Secondary outcomes include total opioid
use, side effects, time spent asleep, patient
satisfaction, length of hospital stay and incremental
cost effectiveness ratio.
Ethics and dissemination: The study is approved
by the South Central—Southampton A Research Ethics
Committee (REC reference 11/SC/0151). Data
collection will be completed by August 2013, with
statistical analyses starting after all final data queries
are resolved. Dissemination plans include presentations
at local, national and international scientific meetings
held by relevant Colleges and societies. Publications
should be ready for submission during 2014. A lay
summary of the results will be available to study
participants on request, and disseminated via a
publically accessible website.
Registration details: The study is registered with the
European Clinical Trials Database (EudraCT Number:
2011-000194-31) and is on the ISCRTN register
(ISRCTN25343280).
INTRODUCTION
Pain is deﬁned as ‘an unpleasant sensory and
emotional experience associated with actual
or potential tissue damage’.1 Pain is the com-
monest reason that patients present to the
emergency department (ED), but it is often
not treated effectively.2 In a national survey
of ED patients, 66% reported they were in
pain.3 The UK College of Emergency
Medicine recommends that patients in severe
pain should receive analgesia within 20 min
of arrival in the ED, with regular reassess-
ment and further action as required.4
However, effective analgesia is often not
achieved and almost half of patients recently
surveyed thought more could be done to
treat their pain in the ED.3
Routine care for patients in moderate or
severe pain often involves the administration
of intravenous morphine, which is the stand-
ard opioid used in most hospitals and has
been shown to be as effective as other
opioids.5 In EDs across the UK, analgesia for
patients in severe pain is currently provided
by nurse-delivered intravenous morphine
administered over several minutes to achieve
pain relief. This technique is safe and effect-
ive in the short term but places signiﬁcant
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demands on nursing time, particularly when repeated
doses are needed.6
Once a patient is admitted to a hospital ward, severe
pain may be managed using strong oral opioid analgesia
or advanced pain management techniques. Best practice
includes multimodal analgesia using regular paraceta-
mol and non-steroidal anti-inﬂammatory drugs
(NSAIDs) in addition to opioids. The decision to admit
a patient to the ward has been shown to delay the deliv-
ery of effective analgesia in the ED—suggesting that this
group of patients are at particular risk of poor pain
management.7
One solution may be to allow patients to deliver
opioid analgesia themselves via a patient controlled anal-
gesia (PCA) device. This device consists of a volumetric
pump, which delivers a set intravenous dose of drug
when a control button is pressed. The PCA system
includes antisyphon and antireﬂux valves to minimise
the risk of inadvertent drug delivery. The pump has a
safety ‘lockout’ period when it does not deliver a further
dose of opioid. A protocol commonly used throughout
many UK hospitals, in settings other than the ED, uses a
1 mg bolus (1 mg morphine) and lockout period of
5 min, and is derived from a broad evidence base.8–11
PCA has been shown to be more effective in providing
pain relief when compared to standard methods of anal-
gesia delivery in areas such as postoperative care, burns
and in terminal care.12–15 PCA is most effective in main-
taining analgesia once baseline pain relief has been
established.16
Despite the high prevalence of pain in ED patients
there is very limited evidence relating to the use of PCA
in this setting. Prior to starting the PASTIES trial, only
one small randomised trial of 86 adult patients with pain
due to trauma presenting to the ED had been pub-
lished,17 which concluded that PCA was as effective as
standard nurse titrated analgesia. However, the trial data
were collected during the patients’ ED stay only, and did
not continue to follow them after admission to a hospital
ward. Having contacted the corresponding author of
this paper, it would appear that the main issue with this
study was that the duration of active participation did
not extend beyond 3 h (Clancy M, personal communica-
tion, 2009).
Three further relevant studies have been reported
since the current study started, although all three studies
were limited to a 2 h period in the ED. The largest,18 a
study done in North America, randomised 211 emer-
gency patients with abdominal pain to one of three
groups; standard care, PCA standard dose (1 mg) bolus
or PCA higher dose (1.5 mg) bolus. It found that there
was a signiﬁcant reduction in pain in both PCA groups
compared to standard care. A smaller study from
Malaysia included patients presenting with pain of trau-
matic origin;19 96 patients in two centres were rando-
mised to either standard care or PCA (1 mg boluses),
with a signiﬁcant reduction reported in pain scores in
the PCA group compared to the standard care group.
The same two authors reported another smaller study of
47 patients with traumatic injury.20 Patients were again
randomised to receive either standard care or PCA
(1 mg boluses). This study found similar reductions in
pain scores in the PCA group compared to standard
care. These three recent studies provide further limited
evidence of the short-term utility of PCA in emergency
patients, but do not address the management of pain
over the subsequent hours following hospital admission.
Cost analyses of the use of PCA versus standard anal-
gesia have been carried out in a postoperative setting
and suggest that PCA costs may be higher.21 However, in
the ED the heavy demands on nursing time of providing
intravenous analgesia may offset the initial high setup
costs of PCA analgesia; this current study will therefore
determine the UK cost implications of PCA use in the
emergency setting over the ﬁrst 12 h of hospital care. No
previous or current studies have been identiﬁed that
combine ED care with ongoing ward care to assess
quality of pain relief beyond 4 h, and no detailed ana-
lysis of the cost-effectiveness of PCA in this setting has
previously been reported.
The aim of our study is therefore to compare PCA
morphine to routine care (nurse titrated intravenous
morphine in the ED and oral or parenteral morphine
on the wards) in adult emergency patients who present
in moderate or severe pain due to traumatic injuries or
non-traumatic abdominal pain, and are then admitted
to an inpatient ward.
METHODS AND ANALYSIS
Study design
The study comprises two contemporaneous multi-centre
open-label randomised trials of PCA versus routine care
in the ED. Patients presenting to the ED requiring inta-
venous analgesia and admission to hospital, with either
traumatic musculoskeletal injury or non-traumatic
abdominal pain, are potentially eligible for inclusion.
Key outcome measures will be collected at baseline and
then hourly for 12 h. While two separate trials are
running (one of patients presenting with traumatic
musculoskeletal injuries, the other with non-traumatic
abdominal pain), both are based on the same protocol,
which is outlined below. Nevertheless, they are consid-
ered as two separate trials since they are powered
separately.
Participants
Eligible patients are adults presenting to the ED with
either traumatic injury or non-traumatic abdominal pain
requiring intravenous opioid analgesia and hospital
admission for at least 12 h from the time of enrolment.
Exclusion criteria are listed in table 1. Study participants
include patients who meet the screening criteria and are
willing and able to give informed consent.
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Study recruitment
Patients are screened by a research nurse on arrival at
the ED. Following an initial assessment and pain man-
agement, patients are approached by a research nurse
and given a patient information sheet detailing the
study. If they are happy to discuss the study further, any
questions are answered at this stage. Patients are then
fully assessed against the inclusion and exclusion criteria
before written informed consent is obtained from the
patients willing and able to participate. Patients who
decline to take part are not obliged to give a reason for
declining but reasons are recorded by the research
nurse if given.
Study procedures
After informed consent is obtained, the ﬁrst visual ana-
logue scale (VAS) pain score is recorded, and the
patient randomised (using a secure web-based random-
isation system) to receive either PCA or routine care
(see ﬁgure 1).
Participants in both groups then receive instructions
on how to complete the VAS scores, which are entered
into a mini ﬂipchart. The participant turns the page of
the ﬂipchart after an entry is made, and the previous
score is therefore not visible for comparison the next
time a VAS score is recorded. Participants in the trauma
group are instructed to record their pain scores on
movement, while those in the abdominal group are
asked to record their pain scores upon deep breathing.
Electronic timers (Casio F-91W digital watches) issue a
bleep every hour as a reminder to the participant to
complete the hourly score, but this bleep is not usually
loud enough to wake the participant from sleep.
Participants are also instructed how to record periods
asleep on the booklet, using a tick box on each page.
Interventions
The participants allocated to receive routine care are
prescribed intravenous morphine while in the ED and
oral morphine (or subcutaneous/intramuscular for
those nil by mouth) when transferred to the hospital
ward. The participants randomised to the PCA group
receive instruction from the research nurse on how to
operate the PCA device, which is set up by the ED
nurses, and initiated with a 1 mg morphine bolus and a
5 min lockout. PCA is continued for a minimum period
of 12 h; in practice ongoing requirement for PCA is
reviewed the following morning by the clinical team.
Participants in both the groups are prescribed multi-
modal analgesia in addition, including paracetamol and
a NSAID unless contraindicated, and are also prescribed
antiemetics as required. Most outcome data are col-
lected for 12 h from the point at which the ﬁrst pain
score is completed. Length of hospital stay and ﬁnal
diagnosis at discharge are collected retrospectively.
Where possible, at the end of the 12 h study period
(or the following morning as appropriate), participants
in both groups are visited by a research nurse to facili-
tate study data collection. The ﬁnal page of the data col-
lection booklet includes a ﬁve-point patient pain
Table 1 Exclusion criteria
Criteria Rationale
Patients over 75 years Altered plasma levels of opioid in this age group for a
given standard dose of PCA
Patients with a reduced conscious level (Glasgow Coma Score
<15)
Will not be able to give informed consent
Inability to operate a PCA device Will not be able to complete the intervention
Patients who cannot understand the study information For example due to pre-existing dementia, learning
difficulties or intoxication. Will not be able to give informed
consent
Patients with chronic pain Altered pain processing or opioid tolerance
Patients who are opioid tolerant or have active opioid addiction Abnormal response to opioids or potential opioid misuse
Patients with a history of renal failure Accumulation of active opioid metabolites
Allergy or other contraindication to morphine
Hypotension (systolic blood pressure <90 mmHg) Morphine may exacerbate hypotension
Patients in police custody, or prisoners
Inability to gain intravenous access Will not be able to receive intravenous morphine
Patients who are likely to be definitively treated in the ED and
discharged, or who are likely to require transfer for surgery
direct from the ED
Will not be able to complete 12 h of VAS scoring
Patients who are pregnant or breast-feeding Altered drug metabolism and fetal/infant opioid effects
Patients on other predetermined analgesia pathway eg, regional anaesthesia
Previous participation in this study
Current participation in another CTIMP
CTIMP, clinical trial of an investigational medicinal product; ED, emergency department; PCA, patient controlled analgesia, VAS, visual
analogue scale.
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management satisfaction score ranging from ‘perfectly
satisﬁed’ to ‘not satisﬁed at all’. There is also a ﬁnal pain
VAS score, collected the following morning, which may
be used to guide analysis of missing ﬁnal data points.
Primary outcome measure
The primary outcome measure is the total pain experi-
enced over the 12 h study period, as captured by hourly
completion of a VAS. The VAS is presented as a 100 mm
horizontal line with verbal anchors at each end of ‘no
pain’ and ‘worst pain possible’. The study participant
selects the point along the line (and marks this point
with a pen) that reﬂects their current pain perception.
Participants record VAS scores at 60 min intervals over a
12 h period. Periods of sleep are also recorded retro-
spectively by the participant.
Secondary outcome measures
Secondary outcome measures include total opioid dose,
opioid side effects, patient satisfaction with pain manage-
ment, proportion of study period with VAS >44 mm, pro-
portion of study period spent sleeping, length of
hospital stay and incremental cost effectiveness ratio
(ICER).
Total opioid dose is recorded from the prescribed
medication administered as recorded on the patient’s
drug chart during the study period. Study observation
charts are utilised for all study participants and are
based on the standard hospital charts: these are com-
pleted as part of routine care by ED nurses in the ED,
and then by ward nurses after inpatient ward admission.
Observations follow the standard of care in each centre.
Typically, this involves observations 1 hourly for 4 hours,
2 hourly for 8 hours and 4 hourly thereafter. In practice,
this will mean hourly vital signs in the ED and 2 h vital
signs for the rest of the study period. Observations
include heart rate, blood pressure, respiratory rate,
oxygen saturations, oxygen ﬂow rate, sedation score
(AVPU) and nausea score (0–2). A research nurse
reviews the observation charts after the 12 h study
period and transcribes out-of-range results into the study
case report form (CRF). Following the participant’s dis-
charge, the length of stay in hospital and ﬁnal diagnosis
at discharge are obtained from the patient
Figure 1 Trial schematic.
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administration system (or equivalent) by the research
nurse and recorded in the CRF.
Randomisation and blinding
Randomisation to either PCA or standard care is under-
taken via a secure web-based randomisation system.
Research team members accessing the randomisation
website do not know the allocation for an individual
patient until the relevant details are entered and recruit-
ment conﬁrmed.
As pain experience over subsequent hours may be
affected by the time of day of recruitment (those
included later in the day will be scoring their pain
during night hours when they may spend a greater pro-
portion of time asleep), randomisation is stratiﬁed by
morning/afternoon admission, as well as by recruitment
centre. Blinding is not possible for this study due to the
nature of the intervention.
Sample size
The main objective of this study is to assess the magni-
tude of any difference in total pain scores between the
PCA and standard care groups, for each population.
Primary outcome data are being collected in terms of
self-reported pain scores over time, with VAS measure-
ments completed hourly over the 12 h study period.
Data will be conceptualised as a graph of VAS pain
against time and used to produce an area under the
curve (AUC) for each patient. This is a measure of
overall pain experienced during the study period.22
Very few studies have addressed the question of what
reduction in AUC might be a clinically signiﬁcant anal-
gesic effect. One study by Camu et al23 demonstrated
that a 20% reduction in the AUC for pain on movement
was associated with a 26% absolute increase in the pro-
portion of patients reporting their global rating of pain
relief as very good or excellent (p=0.01). Conservatively,
therefore, a difference in AUC of 15% between PCA
and standard care groups was chosen to be of clinical
signiﬁcance. On a standardised AUC (scoring between 0
and 100) the standard care group is expected to have an
average score of about 40 units, so 15% equates to a six-
point reduction. A SD can be estimated from the
research conducted by Camu et al23 as about 15 units.
Based on these assumptions, and using a two-tailed two
sample t test, with a type I error rate of 0.05, a sample
size of 100 patients per group provides sufﬁcient power
(80%) to detect a between-group difference of 15%.
Statistical analyses
The primary analyses are all pre-speciﬁed and a detailed
statistical analysis plan will be completed and signed-off
by the data monitoring committee prior to starting
the analyses. Data will be reported and presented
according to the CONSORT statement.24 In the primary
analyses the data will be pooled across all participating
recruitment centres, with adjustment for centre in all
comparative analyses, and with adjustment for time of
recruitment. 95% CI will be calculated and presented
where possible.
The primary statistical analysis will follow an intention-
to-treat approach, with the intent-to-treat population
deﬁned as all participants in the trial who completed
the baseline and at least one other pain VAS. The
primary outcome measure of total pain experienced will
be captured using the area under the curve approach
and will be compared between PCA and standard care
groups using analysis of covariance, which will include
the two stratiﬁcation variables as covariates, both being
considered as ﬁxed effects, with a suitable transform-
ation of the AUC considered if necessary. The estimate
of the difference in mean AUC will be presented,
together with a 95% CI for the difference.
Continuous secondary outcomes will be compared
between the two groups using analysis of covariance,
with adjustment for stratiﬁcation variables and a suitable
transformation of each variable considered if necessary.
For each of the side effects, binary logistic regression
will be used to estimate the OR and 95% CI for the
group effect.
For the analysis of the participant’s satisfaction with
pain management, it is likely that the ﬁve-point scale
(ranging from ‘perfectly satisﬁed’ to ‘not at all satisﬁed’)
will need to be recoded into fewer categories.
Depending on how many recoded categories there are,
either binary or ordinal logistic regression will be used
to determine the OR and 95% CI for the group effect.
Missing data
It was anticipated prior to starting the study that there
would be some missing VAS scores and the original
protocol speciﬁed how both missing data and periods
when a participant indicated she/he was asleep should
be handled within the analysis. However, inspection of
the incoming combined primary outcome data suggests
that there may be a relatively high proportion of partici-
pants with one or more missing pain VAS scores—in par-
ticular, indications of being asleep. As part of the
development of the statistical analysis plan, more
detailed rules for handling the missing pain VAS scores
have been developed for each missing data scenario
(sleep, spoilt, score missing but participant remained in
trial and score missing because participant withdrawn
from trial). In brief, this involves linear interpolation
where the absent pain score(s) falls between two valid
VAS scores, and last observation carried forward where
the absent score(s) extends to the ﬁnal 12 h time point.
The one exception to the latter is when it makes more
sense to impute zero for the remaining scores, in par-
ticular if the patient is discharged because the pain has
resolved; any other such potentially ambiguous situations
will be judged on an individual basis, blinded to group
allocation. Furthermore, a number of sensitivity analyses
are also planned, such as treating all sleep periods as
zero. The strategies have been discussed and agreed
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with the data monitoring committee and will be incor-
porated into the statistical analysis plan.
Economic evaluation
The trial will include a cost-effectiveness study from an
NHS perspective. For the economic evaluation, the rela-
tive effectiveness of the intervention will be measured in
terms of hours in moderate or severe pain averted.
Details of the volume of resources used for pain man-
agement using the PCA or in usual management will be
collected, ignoring resource use that is common to both
study arms. Resource use will be costed using standard
NHS costs. The main drivers of marginal cost in this
study are likely to be medical and nursing time, but the
evaluation will include the costs of medication, equip-
ment and disposables and costs associated with length of
stay. As part of the economic evaluation, an opportunis-
tic sample of up to 20 patients in each arm of the trial
will be observed by a research nurse and the time
required for pain management by healthcare staff will
be recorded. The results of the economic evaluation will
be reported as ICERs deﬁned as the additional cost per
hour in moderate or severe pain averted. Uncertainty
around the estimates of the ICER will be explored using
probabilistic and deterministic sensitivity analysis.
ETHICS AND DISSEMINATION
Ethical considerations
The protocol is designed to conform to the principles
of the Declaration of Helsinki and has been approved by
the South Central—Southampton A Research Ethics
Committee (REC reference 11/SC/0151). A clinical
trial authorisation has been obtained from the
Medicines and Healthcare products Regulatory Agency
(MHRA) and the study runs in compliance with the
Medicines for Human Use (Clinical Trials) Regulations
2004 and subsequent amendments, the principles of
GCP, the Research Governance Framework for Health
and Social Care (Second edition, 2005) and the Data
Protection Act 1998. The study has been adopted by the
NIHR Clinical Research Network (CRN).
The study is sponsored by Plymouth Hospitals NHS
Trust and approved by the participating trust’s research
and development departments at investigator sites. The
study is managed by the UKCRC-registered Peninsula
Clinical Trials Unit at Plymouth University (Registration
No: 31).
A trial management team meets regularly to discuss
the progress of the trial, and address any issues that
arise. A Trial Steering Committee (TSC), with an inde-
pendent chair, meets approximately every 6 months to
oversee the conduct and safety of the trial. A Data
Monitoring Committee (DMC), comprising two inde-
pendent clinicians and one independent statistician,
meets approximately every 6 months to oversee the data
management and any issues relating to patient safety.
The DMC provides recommendations to the TSC follow-
ing each meeting.
The main ethical consideration is that emergency
patients in pain are being asked to participate in a
research study. However, all the patients are initially
treated according to their needs, and only once the
patient has received appropriate initial analgesia and
made more comfortable, are they approached regarding
the study.
Timelines and dissemination plans
Approval from a NHS Research Ethics Committee was
obtained in May 2011. Recruitment and training of staff
involved in the project occurred in June 2011, and
recruitment of participants started in July 2011.
Additional trial centres were added, to improve recruit-
ment, during 2012.
Patient recruitment will complete in July 2013.
Statistical analyses will start once ﬁnal data collection
and monitoring has concluded, and it is anticipated that
the ﬁrst publications will be ready for submission by
early 2014.
As well as the submission of research articles to appro-
priate peer-reviewed journals, research ﬁndings will be
submitted for presentation at local, national and inter-
national scientiﬁc meetings held by, for example, the
College of Emergency Medicine, Faculty of Pain
Medicine and Royal College of Anaesthetists. In particu-
lar, effective dissemination of research ﬁndings through-
out the Emergency Medicine community within the UK
and overseas is anticipated with one of the study authors
( JRB) currently chairing the UK Clinical Effectiveness
Committee of the College of Emergency Medicine. A lay
summary of the results will be available to study partici-
pants on request, and disseminated via a publically
accessible website.
CONCLUSIONS
The lack of evidence regarding the effectiveness of PCA
to manage pain in patients presenting to emergency
departments indicates the need for well-designed clinical
trials to investigate this subject. This study, comprising
two trials in different populations of patients in pain pre-
senting to the ED, has been designed to investigate
whether PCA is more effective than standard care in man-
aging pain in the ED and during the following hours of
hospital admission. This is the ﬁrst study to follow-up par-
ticipants from emergency admission to the hospital ward,
and will therefore give a pragmatic answer to the question
of whether PCA should be used in these patients.
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